Savara Inc. (SVRA)
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SVRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $939.86M
- EPS (TTM)
- -$0.60
- Dividend yield
- None
- 52-week range
- 4.00 – 7.01
- Day range
- 4.00 – 4.52
- Volume / Avg
- 17.01M / 2.79M
- Beta
- —
- Shares outstanding
- 220.62M
52-week range
SVRA stock today
On Nov 20, SVRA ended the session at $4.26, shedding $0.95 (18.23%), versus the S&P 500's 3.70% decline. Volume was 6.1x the average at 17.01M shares, a sign of unusually heavy trading. At this level, SVRA sits near the bottom of its 52-week range of $4.00 to $7.01: 39.2% below the high, set on Dec 12, 2025 and 6.5% above the low.
SVRA is down 29.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.4%. Savara has posted a net loss over the last twelve months (EPS of -$0.60), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Savara
Company profileSavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Matthew Pauls J.D., M.B.A.
- Headquarters
- Yardley, PA
- Employees
- 70
- Website
- savarapharma.com
Financial highlights
Full financialsSavara reported a net loss of $118.8 million, compared with a loss of $95.9 million a year earlier. Diluted earnings per share came in at -$0.53.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-118.84M | $-95.88M | $-54.70M | $-38.15M | $-43.01M |
| EPS (diluted) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$11.06+159.62%
- Strong buy 3
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.17 vs $-0.18
- Surprise
- +5.56%
SVRA news
All SVRA newsSavara peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs SVRA |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs SVRA |
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs SVRA |
| AKTSAktis Oncology Inc. | 16.15 | -1.52% | $901.14M | vs SVRA |
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs SVRA |
| ANROAlto Neuroscience Inc. | 25.37 | -4.30% | $1.02B | vs SVRA |
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs SVRA |
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs SVRA |
Indexes, lists and sector
Savara stock FAQ
What is Savara's stock price today?
SVRA last traded at $4.26 as of Nov 20, 4:00 PM EST, down 18.23% on the day. Prices are delayed at least 15 minutes.
Who is Savara's CEO?
Mr. Matthew Pauls J.D., M.B.A. is the chief executive officer of Savara Inc., which has about 70 employees.
What is the SVRA 52-week high?
The 52-week high for SVRA is $7.01 and the 52-week low is $4.00. The stock is currently 39.2% below its high.